Stage
No active trials
Next date
None yet
Trials
0 active
4 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “AIV001 is administered as a aqueous suspension by an intradermal/intratumoral injection”In the company’s words, NCT04470726 on ClinicalTrials.gov
- Tested for
- Scar (2 trials), Incision (2 trials), Papulopustular Rosacea, Abdominal, Wound (Morphologic Abnormality), Keloid, Excision Margin, Superficial Basal Cell Carcinoma and 2 more
- Main trialPhase 1/2
- “To evaluate the safety, efficacy, and pharmacokinetic profile of ascending concentrations of the study medication compared with vehicle in subjects with rosacea.”In the company’s words, NCT03883945 on ClinicalTrials.gov
Other drugs for Scar
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials4
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Withdrawn | Jul 2022 | A Safety and Efficacy Study to Evaluate Rosacea | |
| Phase 1Completed | 4 Dec 2019 | A Safety and Efficacy Study to Evaluate AIV001 in Wound Healing Following Surgical Incision | |
| Phase 1Completed | 15 Dec 2022 | Safety and Efficacy of AIV001 on Scar Formation and Keloid Recurrence Following Keloidectomy | |
| Phase 1Completed | 20 Jun 2023 | Safety and Efficacy Evaluation of AIV001 in Nonmelanoma Skin Cancer of the Low Risk Basal Cell Carcinoma Subtype |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026